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The present study demonstrates the effectiveness of 
combining medication packaging, verbal and graphical 
feedback, and pill count probes on increasing medication 
compliance. Eight chronic adult outpatients were 
randomly assigned to one of two conditions: (a) a 
regimen card medication packaging system, and (b) a 7-
day baggie medication packaging system. A staggered 
group treatment design was used to ascertain whether 
either of the two special packaging systems was 
effective relative to baseline and reversal conditions 
(using the standard medication vial) in increasing 
medication compliance behavior among both over-and 
undercompliant outpatients. Results indicated that the 
use of the special packaging of medication in 
combination with the behavioral techniques of verbal and 
graphical feedback aided in improving compliance in 4 
out of 8 noncompliant outpatients. 
Improving Medication Compliance With Mentally Disabled 
Outpatients 
Medication noncompliance involves the patients' 
failure to fulfill the requirements of a prescribed 
medical regimen or t o engage in preventive health care 
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(DiMatteo & DiNicola, 1982). It is a serious problem 
with psychiatric outpatients. The reluctance of 
patients t o take their prescribed medications can lead 
to recidivism and rehospitalization (Silberstein & 
Blackman, 1966). A study by Van Patton (1974) estimated 
that from 24% to 63% of psychiatric outpatients take 
less of their antipsychotic medication than the amount 
prescribed. In the psychiatric inpatient population, 
15% to 33% take less than the amount prescribed (Van--
Patton, 1974). 
There are many variables which influence 
noncompliance by psychiatric outpatients to medicat ion 
regimens. Remembering which pill is to be taken is a 
serious problem (Diamond, 1983) . Side effects, such as 
nausea, drowsiness, shaking, and even sexual 
dysfunctions, discourage outpatients from taking their 
medication (Diamond, 1983; Kane, 1983; Michaux, 1961; 
Van Patton, 1974). Patients' own conceptions of their 
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illness is another variable (Jamison & Akiskal, 1983; 
Marston, 1970). If the patient is under an assumption 
that he or she is not mentally ill, or that he or she is 
not ill enough to have to take his or her drugs, 
compliance will be lower (Diamond, 1983; Marston, 1970) . 
Other variables such as availability of transportation 
to obtain medication, money to purchase medication, the 
duration of medication treatment (Jamison & Akiskal, 
1983), conditions in which going off their medication 
makes a patient feel better or, at least, "no worse'' 
(Gillum & Barsky, 1974), and the lack of understanding 
of what their medication does (Diamond, 1983) are all 
factors which contribute to noncompliance . 
. _ _ Ass_es_s_ment _f_or_~tectii1g:_n_()I1_c:ompliance_c~I1 t;ake many 
forms: pill counts (Marston, 1970), urinary analysis 
(Rickels & Briscoe, 1970), trace measures (Roth, Carson, 
& Hsi, 1969), verbal self-reports (Hogan, Awad, & 
Eastwood, 1983), and patients' overt behavior patterns 
(Stewart & Leighton, 1972). Various strategies have 
been developed to combat the problem of noncompliance, 
such as medication education (Cohen & Amdur, 1981), 
behavioral self-help techniques (Olarte & Masnik, 1981), 
and special packaging (Eshelman & Fitzloff, 1976; Irvin, 
1976) • Diamond (1983) stated that outpatients are more 
likely to comply with visual daily regimens of 
medications that are held in plastic containers with 
appropriate labels, time frames, and dates of 
consumption. 
A review of the literature on the measurement of 
noncompliance, the effects of medication education, 
behavioral self-help techniques to increase compliance, 
and the use of special packaging combined with other 
treatments on improving medication compliance with the 
problem client follows. 
Measurement of Noncompliance 
There are four principle techniques used to measure 
noncompliance: urine analysis, pill counts, therapeutic 
interviews, and psychological tests. 
Urine Analysis 
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A urine test can determine whether or not patients 
have consumed their medication by examining urine 
directly (a) for the drug, (b) for a derivative of the 
drug, or (c) for agents added to the drug for purposes 
of detection. Various studies have demonstrated 
successful indications of compliance when implementing a 
urine test (Rickels, & Briscoe, 1970; Silberstein & 
Blackman, 1966; Wilson & Enoch, 1967) . Hare and Willcox 
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(1967) used urine tests on both male and female 
inpatients on two separate psychiatric inpatient wards. 
Their results indicated which inpatients were 
noncompliant and those who were compliant within both 
wards. Wilson and Enoch (1967) collected 25 urine 
specimens from male and female schizophrenic inpatients. 
Specimens were collected after each morning dose of 
medication. Urinary analysis indicated the noncompliant 
patients on the ward, thus alerting the staff as to 
which inpatients were in need of special treatment. 
Unfortunately, information obtained from most urine 
tests is limited in the accuracy of assessing the degree 
of noncompliance (Rickels & Briscoe, 1970) . In 
- -addition,_the_ use____Qf urinal:"y_ analysis may_ cause _J2<it:_ients 
to react to laboratory testing in a negative fashion, 
inducing, for example, paranoia in psychiatric 
outpatients (Rickels & Briscoe, 1970) . 
Pill Cmmts 
The pill count is simple and easily administered. 
It involves providing an exact quantity of medication 
to a patient and counting the number of remaining doses 
at a later date. This technique provides an advantage 
over the urine test analysis in that the presumed amount 
consumed may be determined (Boyd, Covington, Stanasek, & 
Cousson, 1974). However, when using this technique to 
measure compliance, the correct number of pills counted 
does not necessarily mean the patient has taken his or· 
her prescribed amount of medication (Kane, 1983; 
Marston, 1970; Rickels & Briscoe, 1970). Tonguing, 
cheeking, or flushing one's medication have been 
reported in a variety of undercompliant patients (Boyd 
et a1., 1974; Kane, 1983). (It is important to note, 
7 
however, that overcompliant patients do not present this 
problem, for it is difficult for them to replace pills 
they have already taken.) A pill count alone is usually 
not enough to detect compliance among most patients 
(Roth et al., 1969); usually the combination of a pill 
count with urine _Qr blood tests is necessary for 
accurate detection (Kane, 1983; Roth et al., 1969). For 
example, Roth and Berger (1960) studied ulcer patients 
relative to how much antacid they were to take and how 
often. Pill counts were used, followed by a blood and 
tracer technique indicating that patients were taking 
less than half of the amount prescribed. It is 
advisable to use this technique in conjunction with 




Various studies have emphasized the importance of 
the patient-physician relationship in promoting 
medication compliance (Luntz & Austin, 1960; Marston, 
1970). The general purpose of the therapeutic interview 
is to find out how patients are feeling as a consequence 
of taking their medications and how closely they are 
adhering to their prescribed regimen. Adverse side 
effects and a change in symptoms can also be assessed. 
Once a physician can relate to his or her patients in an 
empathetic, nonauthoritarian manner, assessment of 
compliant behavior and education concerning illness and 
medications prescribed can take place (Davis, 1969) . In 
addition, during a therapeutic interview, relating in a 
manner that does not imply guilt on the part of the 
patient and becoming familiar with the patients 
themselves can enhance correct interpretation of 
responses made in order to detect medication compliance 
behavior (Boyd et al., 1974). 
The interview has been used either alone or in 
combination with other techniques such as pill counts 
and tracers (Boyd et al., 1974). It can allow for a 
more in-depth study of subtle i ndications of 
9 
noncompliance. 
Self-report may be an inaccurate or inconsistent 
measure of medication compliance behavior with the 
problem patient. Bergman and Werner (1963) found 83% of 
patients verbally reporting compliant behavior over a 
10-day period. However, objective measures using pill 
counts indicated 82% of the patients had stopped taking 
all their penicillin by the 9th day of treatment. 
The therapeutic interview can serve to help assess 
the actions of the patient that relate to a medication 
compliance problem and to identify events functionally 
related to compliance (Zifferblatt, 1975) . Overall, the 
therapeutic interview is used as a form of assessment in 
---"'hich to_ address_i!n_ci_measurEl __ compliant behavior with the 
problem patient (Davis, 1969; Marston, 1970; Rickels & 
Briscoe, 1970) . 
Self-report 
Patients' self-report measures have also been used 
in medication compliance programs (Epstein & Masek, 
1978). However, they have been found to be unreliable 
in assessing how accurately patients comply with their 
medication regimens (Epstein & Masek, 1978; Haynes, 
Taylor, & Sackett, 1979). The use of other techniques 
with self-report ensures better estimates of compliance 
10 
behavior. 
Behavioral Self-Help Techniques 
Behavior analysis focuses on the immediate 
medication-taking behaviors of the client and the 
related antecedents and consequences. Establishing 
compliant behavior requires identification of the target 
behavior, performing a functional analysis of that 
behavior, and rearranging the environment to facilitate 
the occurrence of compliant behavior. The following 
section reviews the effects of reinforcement, self-
monitoring, and self-medication dispensing on medication 
compliance. 
Reinforcement 
Positive reinforcement provides consequences that 
increase the probability of compliant behavior. Some 
examples of positive reinforcement include verbal and/or 
physical praise for correct responses and self-
administered "treats" contingent upon the client 
engaging in the desired behavior of compliance to 
medical regimens. For example, Olarte and Masnik (1981) 
conducted coffee groups at an outpatient facility in 
order to initiate discussion of medication compliance. 
Therapists met with their patients on a weekly basis and 
participated for an hour and a half in low-keyed group 
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socialization. Therapists encouraged general 
conversation for the first part of the session. The 
second part pertained to medications and prescription 
dispensing. Social reinforcement (meeting with 
therapists outside the normal office setting) and 
receiving free coffee (as a back-up reinforcer for the 
discussion of compliance) combined, led to greater 
compliance in keeping weekly scheduled appointments and 
more open discussion of medication compliance behavior. 
Lowe (1976) studied the effects of reinforcement on 
compliant behavior in a female diabetic. The subject 
had three medical responsibilities: (a)urine sampling, 
(b) diet maintenance, and (c) foot care. The 
intervention involved posted and instructed memos and 
points assigned for completion of each medical 
responsibility. Using horne based treatment, the 
subject's mother instructed each self- care behavior at 
prescribed times to the subject. If the subject 
complied with the designated self-care behavior within 
15 min before or after the time written on her posted 
memo or as instructed by her mother, compliance was 
scored as "yes." If the subject did not comply within 
the time periods allotted, compliance was scored as 
12 
"no." Points were given on a weekly basis for 
compliance with urine sampling and foot care. The 
subject had to earn a total of 12 points for daily 
reinforcers (dietetic sodas and snacks, games, and bike 
rides), and a total of 70 points for weekly reinforcers 
(movies and special trips) . Points were displayed on a 
daily basis in an area prominent to the subject to 
inform her of her level of compliance. Using points to 
exchange for reinforcers, the subject's compliance 
behavior increased substantially in all three self-care 
areas and maintained through follow-up. 
The use of aversive consequences has been successful 
in contingency contracting programs for weight loss and 
(Haynes et al., 1979). Haynes (1973) used a contingency 
management program with 12 alcoholics who had been sent 
to jail. The program consisted of avoiding a jail term 
contingent upon compliance to an Antabuse program for 
the same amount of time as the jail sentence. If they 
dropped out of the Antabuse program, their jail terms 
were reinstated. Results indicated that compliance to 




The process of observing and recording one's own 
behavior has been found to increase compliance among 
many problem patients (Haynes et al., 1979; Sand, 
Frieschmann, Fordyce, & Fowler, 1975). The technique of 
self-monitoring has been widely used in weight reduction 
programs (Haynes et al ., 1979, p. 184). Unfortunately, 
few studies involving self-monitoring with compliance to 
medical regimens have been conducted (Haynes et al., 
1979, p.184). 
Sand et al. (1975) studied the effects of self-
monitoring and reinforcement upon noncompliant self-care 
behaviors. The subject was a 27 year old male 
paraplegic who relied on the nursing staff to do simple 
self-care related tasks that he was capable of doing 
himself (tallying the correct number of medications 
consumed per day, bathing, and dressing). The subject 
was given a list of self-care behaviors to complete for 
each day. As he completed a behavior, he was to check 
it off on the given list and hand it in to one of the 
nurses on duty for the day. During the second week he 
was introduced to more self-care behaviors, and if he 
completed a specified number , he was awarded a pass horne 
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from the hospital. His compliance rate increased over 
the first week and continued to do so for 4 weeks until 
discharged. 
Self-dispensing Medication 
Prompting patients who dispense their own medication 
regimens has also been found to be effective in 
increasing medication compliance (Azrin & Powell, 1969). 
Such programs usually involve reminder tactics in order 
to increase the likelihood of compliant behavior. 
Azrin and Powell (1969) examined the effects of 
self-medication dispensing using an operant apparatus 
based on response priming and escape reinforcement. The 
apparatus was used with 6 normal adults instructed to 
comply with a medical regimen. The portable apparatus 
would sound a tone during a given time frame~thus 
alerting the subjects to switch a lever in order to 
terminate the loud tone and eject a tablet providing 
escape reinforcement. This prompting device was 
compared to that of a normal wristwatch. Results were 
that 97% of the subjects followed their prescribed 
medical regimens using the portable apparatus as opposed 
to 16% compliance when using normal wrist watches. The 
authors concluded that the use of response priming can 
be effective in increasing compliance with a variety of 
patients, especially in the psychiatric population. 
15 
Combining Techniques 
Epstein and Masek (1978) used a variety of 
behavioral procedures to increase medication compliance. 
Seventy-two undergraduate college students participated 
in complying to a vitamin C regimen for a 6 week period . 
Compliance was assessed by a tracer which discolored 
urine; subjects were to report the time of discoloration 
to the experimenter. This report was compared to the 
predicted time on the basis of a scheduled sequence of 
vitamin C tablets with a chemical tracer. Subjects were 
randomly assigned to 4 groups: self-monitoring, taste, 
taste plus self-monitoring, and a no-treatment control 
group. Half of the students in the above groups 
participated in a response cost procedure. The results 
revealed that the self-monitoring, and taste plus self-
monitoring procedures yielded the most appropriate 
levels of medication compliance. The response cost 
procedure also produced a marked improvement in 
compliance. The t aste plus self-monitoring procedure 
was not significantly different from the results of the 
response cost procedure a l one on improving medication 
compliance. 
In summary, the effects of positive reinforcement, 
self-monitoring, self-medication dispensing, and the 
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combination of these techniques have proven to be very 
effective procedures in enhancing medication compliance 
behavior. These techniques enable clients to learn how 
to help themselves and not to be dependent upon others 
to help them maintain effective and productive lives. 
Patient Education 
McEvoy (1981} found that 60% of the clients he 
studied had a poor understanding of their need for 
hospital admission and 56% did not understand their need 
for medication. Lin, Spiga, and Fetsch (1979} found 
that only 31% of clients had insight into their illness. 
Various studies have found medication education 
effective in increasing compliance with a variety of 
populations (Cohen & Amdur, 1981; Haynes et al., 1979; 
Hecht, 1974}, and physicians, nurses, and community 
health workers communicating to clients what their 
medications do to help them has been a component in many 
compliance programs (Marston, 1970} . 
Hecht (1974} studied 47 tuberculosis outpatients, 
all of whom (a} had a medication regimen including 
isoniazid, (b) had a negative history of drug addiction 
or recent psychiatric illness, (c) lived at home, and 
(d) were referred to a clinic in need of assistance to 
comply with a medical regimen. The objective of the 
17 
study was to teach each patient as much as possible 
about the drugs administered, to reinforce what they 
already knew about their medication, and to correct any 
misinformation. Three experimental groups received 
varying amounts of medication information and individual 
instruction by nurses. Group I was taught about 
medications administered in the clinic, Group II was 
taught within the clinic and in two horne visits about 
the effects of their medication, and Group III was 
taught in the hospital before discharge and in the 
clinic of their illness and medications prescribed. 
Results derived from interviews and pill counts 
indicated noncompliance was reduced from 53% in the 
control group to 17% of the patients in the group which 
received the most intensive instruction. 
Cohen and Amdur (1981) examined the effectiveness of 
group education to increase compliance in psychiatric 
patients. Six separate group meetings were devised to 
help patients understand the role that psychotropic 
drugs play on maintaining mental health. A variety of 
problem-solving and task-oriented approaches were used 
in the meetings to help patients gain insight into their 
own feelings and perceptions about taking medications. 
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Each group meeting used a question-and-answer format, 
with questions answered by either staff or group 
members. Each group had 6 to 10 patients and met weekly 
for 1 hour. Compliance to medical regimens was measured 
by a pre-and post-questionnaire. Results indicated an 
increase in overall understanding of psychotropic 
medications and in compliance with prescribed medication 
regimens. 
Stowell (1983) studied the effectiveness of 
education on medication compliance in schizophrenic 
outpatients. Subjects were enrolled in a Day Treatment 
Center and followed a workbook as part of weekly 
scheduled group meetings. Education groups consisted of 
hourly meetings pertaining to the understanding of 
----------- ---- --------- --- ---------
medication compliance, the symptoms of psychosis, and 
the understanding of schizophrenia. Participants in the 
groups varied from week to week. The pre-and post-
education results of 5 participants were analyzed. The 
education group increased all 5 participants' 
understanding of medication and increased self-reported 
compliance to medication. 
Patient education has proven to be a beneficial 
component in medication compliance. Often clients lack 
the proper understanding of their medication, its 
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purpose, and the importance of complying to their 
prescribed regimen. The above studies indicate that 
providing clients with such information is beneficial to 
their adherence to and maintenance of their medical 
regimens. 
Special Packaging Combined With Other Treatments 
The effects of special packaging on increasing 
medication compliance has been well documented 
(Demetral, Gipson, Irvin, Anderson, & Catania, 1978; 
Eshelman &, Fitzloff, 1976; Irvin, 1976; Linkewich, 
Catalano, & Flack, 1979) . Special packaging visually 
prompts patients when each pill is to be taken and when 
a pill has and has not been taken. Such packages have 
been found to be successful in increasing medication 
compliance and are preferred by most outpatients in 
comparison to the more typical medication vials 
(Diamond, 1983) . The combining of techniques such as 
pill counts, tracers, education, and behavioral 
techniques with special packaging has demonstrated 
significant increases in compliant behavior (Rehder, 
McCoy, Blackwell, Whitehead, & Robinson, 1980) . 
Eshelman and Fitzloff (1976) studied 100 
hypertensive outpatients all taking the drug 
chlorthalidone. Patients were randomly assigned to 
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using either a medication vial or a special packaging 
technique referred to as PAK. Sixty-seven patients 
received urinary analysis and pill counts to measure 
compliance. Based on the urinary analysis, the patients 
receiving the PAK were significantly more compliant than 
those receiving the medication vial. There was no 
difference evident in compliance rates as measured by 
the pill count. Results of the pill counts indicated 
that patients who received chorthalidone in vials were 
61% compliant, . as compared to 63% using the PAK, for an 
overall rate of 62%. Urine analysis revealed 69% 
compliance using the vials, 93% using the PAK, and 80% 
for an overall rate, respectively. 
Rehder et al. (1 980) also studied 100 hypertensive 
outpatients. Patients in this study attended a 
hypertensive clinic and were prescribed several 
medications a day. Patients were randomly assigned into 
one of four groups: (a) control, (b) received 
counseling, (c) received a medication packaged 
container, and (d) received the medication package 
container plus counseling. Counseling was done by 
physicians, nurses, and pharmacists within a c linic. 
Attendance of group meetings and visits to the pharmacy 
21 
were tallied throughout the study. Results indicated 
patients in the medication package container and 
medication package plus counseling groups demonstrated 
95% or greater compliance, while control group 
compliance was 65%, and the counseling-only group 
compliance 70%. Most of the patients within the study 
commented that they liked the medication packaging 
container better than the medication vials for the 
following reasons: medications were easier to take from 
the container, the medication packaged container helped 
them to remember to take their medications, and lastly, 
the medication package container helped their family 
members to remind patients to take their medication. 
Young (1983) examined special pill containers as 
opposed to vials with 70 hypertensive outpatients. All 
70 outpatients were obtained from an outpatient clinic 
and randomly assigned to one of two groups. Group I 
received a special pill container and a posttest; Group 
II received regular medication vials and a posttest; 
Group III served as the control and received the 
posttest only. Treatment was conducted over a 6 week 
period. The special pill container held medication in 
plastic compartments on cards with labels indicating the 
time and day each pill was to be taken. A new 
22 
medication card was distributed each day. Compliance 
was determined by a urine tracer of hydrochlorothiazide, 
pulse readings, blood pressure readings, and pill 
counts. All readings took place during each client's 
visit to the outpatient clinic. Results revealed 
compliance in the experimental group exceeded 68 . 6%, 
while the control group reached 48.6%. 
Joyner, Fikrat, and Catania (1983) examined the 
effects of special packaging combined with medication 
·monitoring, reinforcement, and home interviews with 
geriatric patients. Fourteen patients participated in 
an 18-month study. Treatment consisted of weekly visits 
to the patient's home by clinical pharmacists assessing 
compliance with medication, counseling on medication, 
distributing medication in special packages, and 
reinforcing with physical and verbal gestures. All 
patients resided in a home for geriatric patients and 
were referred to the program by their physician and/or 
family members as having a problem in medication 
compliance. Results demonstrated that compliance to 
medical regimens ranged from 82% to 100%. I t was 
determined that special packaging and combined 
treatments were able to increase compliance in all 
patients, which was maintained throughout follow-up. 
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A study by Linkewich, Catalano , and Flack (1979) 
examined special packaging and instruction on 
outpatients' compliance to medical regimens. One 
hundred and twenty outpatients were prescribed 
penicillin tablets, one tablet four times a day for a 10 
day period. All outpatients were randomly assigned to 
one of four treatment groups. Group I received 
penicillin in a medication vial with instructions on the 
label. Group II received penicillin in a medication 
vial and a calendar prepared with the dates of therapy 
and antibiotic administrative times recorded on it. 
They were to check off each time they took their daily 
dose of medication using this calendar. In addition 
they were given an instruction card describing the 
regimen they were to follow, which was read to them by a 
pharmacist. Group III received 40 unit dose packages of 
penicillin in the form of special packaged regimen 
cards. They also received a standard label of 
instructions on the package and an instruction card. 
Group IV received a Wyeth QUID Strip-PAK with standard 
labels and instructions. Outpatients were read 
instructions and were given a card, as were patients in 
Groups I, II , and III . Unannounced home visits by a 
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pharmacist took place during the 7th and 9th day of 
treatment for pill counts. Results revealed that Groups 
II, III , and IV ingested a higher percentage of 
penicillin than outpatients in Group I. Pill counts at 
the time of the unannounced interviews indicated that 
all outpatients were still taking their medication and 
following their prescribed regimen. Drug taking was 
arbitrarily considered as compliant if at the time of 
the interview they had taken 90% to 110% of the 
prescribed quantity. Thus, groups receiving special 
packaging had higher compliance to the penicillin 
regimen than those using the medication vial. 
Irvin (1976) studied the use of pill counts and the 
Medi-Dose/Medi-Cup system with verbal reinforcement with 
-----
6 psychiatric outpatients. Each patient's regimen was 
sealed with information on a card indicating the date, 
day of the week, and the time of day to consume 
medication . On the reverse side of the card was the 
name of each medication, strength of medication doses, 
and prescription number. Daily unit dose cards were 
housed in a file box-like container to keep cards in an 
orderly fashion . Pill counts were made by the 
experimenter on several unannounced horne visits during 
different times of the day. The results obtained showed 
an increase in compliance in 4 of the 6 patients. 
Effects of the use of verbal reinforcement (such as : 
"You're doing fine"; "Keep up the good work"), was 
unclear. With the withdrawal of this variable in the 
second treatment phase , it was noted that there was no 
deterioration in compliance behavior. 
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Prompts and reinforcers accompanied by special unit 
dose packaging were assessed by Demetral et al. , (1978). 
Two separate studies were completed, differentiated by 
the presence of an additional treatment phase in the 
second study . The studies consisted of baseline and 
reversals, using vials, special packaging, and verbal 
reinforcement (such as positive praise: "Keep it up 
you ' re doing great!") and a final phase using special 
packaging , alone , in Study Number Two. The first study 
consisted of 8 subjects, and the second study used 6 
subjects. All patients were obtained by referral from 
psychiatrists in a county/state inpatient facility . 
Special unit dose packages of medication were displayed 
on cards, enabling patients to visually ascertain if 
they had taken daily doses of medication. The results 
of both studies yielded 81% to 100% from baseline to 
treatment phases in all 14 patients ' compliant behavior 
using special packaging, verbal reinforcement, and 
special packaging alone. 
26 
The present study attempted to demonstrate the 
effectiveness of combining some of the treatments and 
assessment techniques reviewed above, using special 
packaging techniques, and pill probe counts, in addition 
to verbal and graphical feedback. It was hypothesized 
that special packaging of medication would yield more 
appropriate levels of compliance in comparison to the 
standard medication vial. In particular, the special 
packaging technique of a regimen card was hypothesized 
to yield more appropriate levels of compliance in 
comparison to a 7-day plastic baggie special packaging 
technique. Further, patients who take too much of their 
prescribed medications served as some of the 
participants. Primary attention in past studies has 
focused on the undercompliant patient. However, 
patients who abuse or take too much of their prescribed 
regimen, are also in need of assistance. Abusive 
patients also provide a better measurement of compliance 
when using pill counts, since the patient cannot distort 
the pill count to appear to be compliant through 
disposing of medications by flushing them down the 
toilet or cheeking, hiding pills between the gum and 
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cheek, etc . This study investigated the utility of 
combining various techniques with both abusive and 
undercompliant chronic psychiatric outpatients in order 




The participants consisted of 8 chronic mentally ill 
outpatients, ranging from 29 to 60 years of age. All 
clients were obtained from either the University of the 
Pacific's Community Re-entry Project Medication 
Compliance Program, San Joaquin County Mental Health 
Center's Day Treatment Program, or from the head 
Clinical Pharmacist at San Joaquin County's Mental 
Health Center. All clients were referred to the present 
study due to their past history of suspected 
noncompliance either in the form of abusive or 
undercompliaot behavior on a daily or weekly basis 
(including taking all their medication at one time, 
taking more or less than prescribed at one time or 
another, and/or selling their medication). 
Client 1 was a 60-year-old, divorced, Caucasian 
female, who carried the diagnosis of paranoid 
schizophrenia. She had a reported long history of abuse 
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with her antiparkinson medication. Client 2 was a 37-
year-old, Caucasian male . He was divorced and carried 
the diagnosis of paranoid schizophrenia. In addition he 
had a reported long history of drug abuse and 
overmedicating with his medication regimen. He had been 
known to buy his antiparkinson medication on the street 
when he ran out of his weekly supply . Client 3 was a 
42-year-old single , Black army veteran. He he l d the 
diagnosis of schizoaffective disorder and was reported 
to be both over- and undercompliant with different 
components of his medication regimen. Client 4 was a 
35-year-old single , Caucasian male. He was reported to 
often forget to take his medications and was therefore 
undercompliant; he carried the diagnosis of manic 
depressive illness with paranoid tendencies. Client 5 
was a 46-year-old, divorced, Caucasian male. He had a 
reported history of undercompliance to his medication 
regimen and was diagnosed as a chronic schizophrenic. 
Client 6 was a 43-year-old, Caucasian, recently divorced 
male. In the past he had had a reported history of 
sporadic undercompliance, and he was diagnosed as a 
paranoid schizophrenic, chronic, with acute 
exacerbations. Client 7 was a 36-year-old, divorced, 
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Caucasian female. She was divorced , with a reported 
history of undercompliance and abuse with several of the 
medications in her medical regimen. She was diagnosed 
as having an adjustment disorder , mixed, with 
depression. Client 8 was a 29-year-old, single , Mexican 
male. He had a reported long history of drug and 
alcohol abuse. He was both over-and undercompliant with 
components of his medication regimen and carried the 
diagnosis of chronic schizophrenia, undifferentiated. 
Data pertaining to demographic information and each 
client 's medication regimen were obtained at the end of 
the study and can be found in Table 1. Clients' 
regimens were changed periodically throughout the study 
by their physicians, the regimens listed in Table 1 are 
those that the clients were adhering to at the end of 
the study. 
Materials 
Participant recruitment. A formal letter was sent 
to the Director of Outpatient Services , the Director of 
Community Treatment Services , the Director of Day 
Treatment Services , and Clinical Head Pharmacist, all at 
San Joaquin County ' s Mental Health Center (Appendix A). 
This letter described the study, the clients needed for 
participation in the study, and the dates the study 
would begin and end. 
This was followed by several phone calls to set up 
personal meetings with the Directors and the Head 
Pharmacist. Each meeting entailed a complete 
description of the proposed study, including a 
description of the objectives of the study, the 
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hypothesis, a demonstration of the medication packaging 
systems that were used, the specific time and date that 
the study would begin and end, and the dates clients 
would be on baseline and treatment packages. 
Table 1: Demographic Medication Data 
CLIENT MEDICATION STRENGTH REGIMEN 
1 Anane 5mg 1 tablet, 2 times daily 
2 Anane 5mg 1 tablet, 3 times daily 
Tofranil 25mg 1 tablet at bedtime 
Cog en tin 2mg 1 tablet, 2 times daily 
3 Lithium 300 mg 2 tablets, 2 times daily 
Anane 100 mg 1 tablet at bedtime 
4 Lithium 300 mg 1 tablet, 3 times daily 
Mellaril 100 mg 1 tablet, at bedtime 
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5 Prolix in lOmg 3 tablets at bedtime 
6 Loxitane 50mg 2 tablets at bedtime 
Artane 2mg 1 tablet, 2 times daily 
7 Lithium 300mg 1 tablet, 2 times daily 
Navane 5mg 1 tablet, 3 times daily; 
and 2 at bedtime 
Lithium 50mg 1 tablet 2 times daily; 
and 4 at bedtime 
8 Loxitane 25mg 3 tablets at bedtime 
Artane 5mg 1 tablet, 2 times day 
Table 1: Demographic Data 
Client #1 Client#2 Client #3 Client#4 
Sex F M M M 
Age 60 37 42 35 
Race Caucasian Caucasian Black Caucasian 


































































Table 1: Demographic Data Continued 
Client #5 Client #6 Client #7 
M M F 
46 43 36 
Caucasian Caucasian Caucasian 
Divorced Divorced Divorced 
23 20 6 
1 2 5 
Chronic Paranoid Adjustment 













Undercompliant Yes Yes Yes Yes 
Abusive No No Yes Yes 
Genetic Yes Yes No No 
Environmental No No Yes Yes 
History of No No No Yes 
Abuse 
Following these steps, I sent a letter to all of the 
outpatient doctors, social workers, and case managers 
signed by the Directors of Outpatient Services and of 
Community Treatment Services, to inform them of the 
study and to ask if they had any clients who would 
benefit from such a program (Appendix A) . All referrals 
were made to the Head Clinical Pharmacist, who drew up a 
list of possible clients to participate. 
Referral card/consent form. Each client's social 
worker, case manager, or outpatient doctor was required 
to fill out a referral card/consent form indicating the 
client's name, address, phone number, diagnosis, 
medication(s), and degree of noncompliance in the form 
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of antecdotal reports written at the bottom of the card 
(Appendix B). I obtained the form and kept it on file . 
An additional referral card/consent form was obtained at 
the end of the study from each client ' s doctor during an 
informative meeting describing the client's progress 
while in the medication compliance study . The 
additional referral card/consent form was collected to 
refer the client's to either (a) the Medication 
Compliance Program at Community Re-entry Project; (b) 1-
day medication compliance at the Mental Health Center; 
or (c) weekly medication compliance at the Mental Health 
Center, utilizing any of the packaging systems used in 
the present study after it had ended. This referral 
card/consent form was returned to the Mental Health 
Center's pharmacy for their records. 
Reguest-for-doctor ' s-assistance form. The physician 
of each client referred to the present study was given a 
request for assistance and permission form to sign for 
their client's admittance into the medication compliance 
study (Appendix C) . This form described the packaging 
system of the regimen card and 7-day baggie system and 
the purpose of special packaging techniques . 
Consent for participation in the medication 
compliance study. Each client who participated in the 
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study was required to read, sign, and date a consent 
form indicating that they agreed to participate in the 
medication compliance study (Appendix D) . In addition , 
this form stated that clients al l owed me access to their 
personal outpatient files, to have their prescriptions 
filled at the Mental Health Center ' s Pharmacy, and t o 
have their medication packaged i n the regimen ca rd, 7-
day baggie system, and the medication vial . This f orm 
also indicated that the packaging systems used were not 
child resistant and that all packages shoul d be kept out 
of children ' s reach. 
Special Packaging Techniques 
The medication vial . Al l 8 clients received a 
medication vial with prescribed medication for a 7 day 
interval . Each vial had a label with written 
instructions indicating the type(s) of medication , 
dosage(s) prescribed, and the time intervals in which 
they were to be taken (Figure 1). Each c l ient's 
prescription was filled by one of the c l inical 
pharmacists at the San Joaquin Mental Health Center ' s 
pharmacy . Each client's medication regimen was 
specially packaged by a University of the Pacific 
pharmacy intern apprenticing at the Mental Heal th Center 
Pharmacy, and then it was labeled appropriately and 
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picked up by me to be hand delivered to each client on a 
weekly basis. 
The regimen card package. The regimen card was 17.8 
x 12.7 em of thin cardboard with written instructions 
indicating the days of the week and time intervals in 
which medication was to be taken (Figure 2). Daily 
doses of medication(s) were held in small see-through 
plastic bubbles on the card to clearly indicate if the 
client had or had not taken his or her correct dosage of 
medication. The medication was removed from the bubbles 
by depressing the see-through bubble with an index 
finger. Each client's medication was packaged and 
obtained by the same personnel as those who did the 
medication vial. 
The 7-day baggie package. Clients using the 7-day 
baggie package received seven separate clear zip-lock 
plastic baggies. Each baggie contained the client's 
prescribed medication(s) regimen for a particular day, 
including the specific intervals in which they were to 
be taken (Figure 3) . Instructions indicating the time 
intervals for drug consumption were written on each 
baggie. Medication in each baggie was individually 
stored in smaller zip-lock bags with the appropriate 
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labels, instructions, and intervals in which 
medication(s) were to be consumed. Each client's seven 
baggies were delivered in a larger bag, the larger bag 
thereby containing a weekly regimen of medication. Each 
client ' s medication was obtained and packaged by the 
same personnel who did the medication vial and the 
regimen card packaging systems. 
Feedback form . At the end of each week of 
treatment, I presented the clients a line graph of the 
data obtained from (a) collecting the medication package 
used the week before and from counting the number of 
pills remaining compared to the number that should be 
there according to the client's prescribed regimen, and 
from (b) the one weekly unannounced pill probe count by 
myself. The line graph was used to show clients their 
weekly l evel of compliance throughout the study (Figure 
4) • 
Verbal feedback. At the end of each week during the 
collect ion of the "used packaging" systems from the week 
before and the dispensing of the new week's medications , 
clients received feedback on their compliance behavior. 
At this time, line graph data of each client's progress 
throughout treatment were shown to all clients. Clients 
were reinforced by positive feedback statements 
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including: 
"Look Joe, out of an entire week's supply of 
medication, you only missed two pills! That 's very 
good; next time let's try to get this number down to one 
or zero pills missing. I can see both from this line 
graph and when I come to visit you that you are doing 
well and trying hard. Keep up this good work, I'm proud 
of you!" 
Figure 1. The medication vial containing a week's 
prescribed regimen of medication, with instructions 
indicating the name of medication, dosage(s), and time 
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Figure 2 . The regimen card packaging technique, 
containing a week's regimen of medication, with 
instructions indicating the days of the week and time 
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Figure 3. The 7- day baggie packaging technique 
containing a week's regimen of medication , with 
instructions indicating the dosages and time intervals 
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Figure 4. The feedback form, used to inform 
clients of their weekly level of compliance, visually 
through a line graph presented at the end of each week. 
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Design 
All 8 clients were randomly assigned to groups with 
an equal number of clients in each group (Table 2). 
Group I received the regimen card package and Group II 
received the 7-day baggie package following the initial 
baseline phase. The initiation of treatment was 
staggered so that Group I received treatment after 1 
week of baseline, while Group II received treatment 
after 2 weeks of baseline. All treatment phases lasted 
a period of 2 weeks. The first treatment phase for each 
client was referred to as Treatment A, the second phase 
as Treatment B, and return to use of the vials was 
referred to as reversal~ Following the first treatment 
phase, lasting 2 weeks, clients were returned to using 
the baseline package of the medication vial for 2 weeks, 
and then placed on the treatment package they had not 
yet used for 2 weeks, with a final return to the 
medication vials for another 2 weeks. During the last 2 
weeks of treatment, clients were to pick, out of the two 
medication packaging systems and the medication vial, 
the one they wanted to use for the last phase of the 
study, referred to as Treatment C (or Reversal 3 if they 
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selected the vial) . The performances of both Groups I 
and II were compare d to their own performance using the 
medication vial throughout the study. Both groups were 
compared to evaluate which treatment package was more 
effective in producing appropriate medication compliant 
behavior. 
Table 2: Design Of The Study 
Group 1: Baseline and intervention sequence; two pill probes conducted each week 
throughout the study. 







Treatment A cards 
Reversal 1 vial 













Reversal 2 vial 2 weeks 10-11 
Reversal 3 vial 2 weeks 12-13 
or 
Treatment C cards or baggies 2 weeks 12-13 
Group 2: Baseline and intervention sequence; two pill probes conducted each week 
throughout the study. 
Phase Packaging System Length of Phase Actual Weeks 
Baseline vial 3 weeks 1-3 
~aseline/ vial - 14 weeks- 4-throughout 
Introduction 
to feedback 
Treatment A baggies 2 weeks 5-6 
Reversal 1 vial 2 weeks 7-8 













Definition of compliance. Compliance in this study 
was defined in terms of how closely clients followed 
their prescribed medication regimens. If it was found 
that the client was behind or ahead of his or her weekly 
medication regimen by one or more pills at an 
unannounced pill probe on any of the prescribed 
medication(s), the client was considered noncompliant . 
Each client followed his or her prescribed medication 
regimen in dosage(s) and within the correct time 
frame(s) in order to be cons idered compliant. A mean 
from 80% to 100% was designated as the set point for 
appropriate compliant behavior in relation to each 
c l ient' s medication regimen. 
Procedure 
Baseline . Group I received 1 week of baseline and 
Group II received a 2 - week baseline period. At this 
time clients were instructed to comply as they normally 
would if not in the program, using the medication vial . 
Each client was told: 
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" I will be handling your medication under the 
medication compliance study in which you have consented 
to participate . I will pick up your weekly medication 
regimen and deliver it to you r home every Friday , at 
which time I will collect the vial used the previous 
week. In addition I will make one other visit to your 
home each week to see how you are doing on your 
medication, to see if you have any personal requests 
regarding your medication, and to count the number of 
pills remaining in your vial and compare that to what 
your prescription(s) have indicated t hat you should be 
taking." 
Following these instructions, clients were then 
placed on the medication vial for 2 weeks . One random 
unannounced pill probe was conducted per week in which I 
counted the number of pills taken and compared that 
number with the prescribed regimen . I made unannounced 
pill probes checks during the time frames specified by 
each client as those in which they were most likely to 
be at home. The specific times and day for each home 
visit differed each week according to the client ' s 
schedule, about which they informed me upon delivery of 
medication during the preceding week. Several possible 
days and the time frames per day of availability were 
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determined each week for pill probes; the day and time 
of day selected was randomly picked for each week of the 
study. A schedule was kept indicating the sequence of 
days and time frames I visited each client for the 
unannounced pill probes . If the same day or time frame 
matching the preceding week was picked, I made another 
random selection of a time to make the unannounced 
visit. If by chance the client was not at home, another 
unannounced home visit was made later on that day or the 
day after. As many trips as necessary were made to the 
client ' s home to obtain the information needed for the 
pill probe checks. 
Treatment. Following baseline, clients in Group I 
continued on the medication vial for an additional 2-
week period. At this time I provided them with both 
verbal and graphical feedback at the end of each week, 
upon the collection of the old medication packaging 
system. Verbal and graphical feedback was continued 
throughout treatment . In addition, I presented Group II 
verbal and graphical feedback following baseline. 
At the staggered implementation of treatment, 
clients were placed on the packaging system in 
accordance with the group to which they were randomly 
assigned to during baseline . Group I received the 
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regimen card package for a 2-week period. I gave each 
client a complete demonstration on how this package 
worked. I informed clients that I would deliver their 
weekly medication regimen, collect the medication 
package from the week before, regardless of the number 
of pills missing or remaining, and that I would make one 
weekly unannounced pill probe check on their medication. 
These instructions were the same for those in Group I as 
in baseline. I presented verbal feedback to each client 
regarding appropriate compliant behavior, and data was 
presented visually on a line graph to show the changes 
in compliant behavior compared to baseline data. Verbal 
and graphical feedback data were followed by the same 
instructions as those given during baseline. If the 
client was behind or ahead of his or her weekly 
medication regimen by one or more pills, I gave 
corrective feedback. Corrective feedback included such 
statements as: "Joe, out of a week's regimen of 
medication you have missed eight of your pills. Can you 
explain this to me and why? Next time let's try to 
decrease this number by at least two. Your medication 
compliance behavior is important. It will help to keep 
you well and out of the hospital. Try a little harder 
50 
to remember when and when not to take your pills for the 
next week." 
Following the 2 week period on the regimen card, 
clients returned to the medication vial for an 
additional 2 weeks. Afterwards clients were placed on 
the 7-day baggie system for 2 weeks. A complete 
demonstration with instructions on how to use this 
package was offered by me. Following this 2-week phase, 
clients returned to the medication vial for an 
additional 2 weeks. Pill probe counts, line graphs, and 
verbal feedback given initially on the regimen card 
packaging system occurred throughout subsequent reversal 
and treatment phases. 
I asked each client the best times during the day to 
find him or her at home to receive medication(s). In 
addition, each c lient ' s phone number was obtained to 
check the times each week that he or she was home. 
Group II received the 7-day baggie package for a 2-
week period. I showed each client how this package 
worked. Clients were required to comply with one weekly 
unannounced medication pill probe check, provide me with 
the remaining package from the week before, and to 
comply as best they could throughout the treatment 
phase . Following a 2 week period on the 7-day baggie 
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system, clients returned to the medication vial for an 
additional 2 weeks. After this time period, clients 
received the regimen card packaging system for 2 weeks. 
I gave a complete demonstration with instructions on how 
the regimen card packaging system worked. Following 
this 2-week period on the regimen card package, clients 
returned to the medication vial for an additional 2 
weeks. The instructions, graphical data, and verbal 
feedback given to the clients in Group I were the same 
for the people in Group II. At the end o f treatment, 
clients in both groups were shown graphically, their 
level of medication compliance for the ent ire study . I 
pointed out which medication(s) were either missed or 
abused and pointed out their mean level of medication 
compliance in such statements as: "You had some 
difficulty at the beginning of the study, but now you 
have obtained a mean of medication compliance 
behavior. This is a marked improvement. 
Congratulations!" Or , if the client had demonstrated 
progressively poorer medication compliance behavior, 
structured feedback such as: 
"Joe, after reviewing your data, it does not appear 
that you have increased your medication compliance 
behavior and you have actually gotten worse. You should 
consider the Community Re-entry Medication Compliance 
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Program on a long term basis to help you in taking your 
medications." 
The clients were encouraged to comment on the 
special packaging systems used as to their preference 
and asked if they felt the combined techniques of 
special packaging, pill probe counts, and weekly verbal 
and graphical feedback aided in compliance behavior. I 
then told told them they had the option to either 
continue in a modified program at Community Re-entry 
Project or return to their regular method of medication 
dispensing. This decision was ultimately made by the 
client and his or her case worker or physician. 
Results 
The mean percentages of each client's medication 
compliance behavior were taken throughout the study. To 
obtain a figure representing the percentage of pills 
that were consumed by each client at the time of the two 
weekly pill probes, the number of pills taken was 
counted and that number was divided by the actual number 
prescribed; this number was multiplied by 100. Appendix 
E presents the raw data for each client calculated 
throughout the study for Groups I and II. 
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Figure 5 Client One was abusive with Artane, and 
compliant with Elavil . The medication of Elavil was 
added to her regimen during Reversal 3 . Axis x denotes 
the percentage of compliance ; axis y designates the 
number of pill probe days. 
Cl ient One . This client was referred to the study 
by her case worker due to her reported severe long- term 
medication compliance behavior of overmedicating with 
her antiparkinson medication of Artane (Figure 5) . 
Dur ing the 3 weeks of basel ine (Weeks 1-3), the client 
obtained a mean of 104.4% with a standard deviation of 
16 . 4% while on Artane (which was not representative of 
her reported past abusive behavior patterns as indicated 
by her pharmacist and psychiatrist) . During Weeks 2-3 , 
the presentation of verbal and graphical feedback was 
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introduced. The client's behavior continued to 
fluctuate both above and below satisfactory levels of 
compliance upo n the initiat i on of feedback. Overall 
levels of compliance during treatment phases was 124.9%, 
with a standard deviation of 4.4 % for both medications. 
She obtained an average of 119%, standard deviation of 
16.5%, while on Artane, and 99.8 %, standard deviation of 
13%, on Elavil, after its introduction during the last 
phase of treatment. 
During the first phase of the study, indicated as 
Treatment A, the client was instructed to obtain her 
medication from the special packaging technique of the 
regimen card. The implementation of this technique 
yielded a mean of 121.8%, standard deviation of 13 . 3%, 
indicating a slight elevation in overmedicating, in 
comparison to baseline measures. Treatment B, using the 
7-day baggie packaging system, indicated a slight 
improvement in compliance to a mean level of 128 %, with 
a standard deviation of 16.2%. This figure was 6.2 
percentage points higher than when using the regimen 
card packaging system, and 40.5 percentage points 
improvement in compliance when compared to the reversal 
with the vial. 
Overall reversal phases indicated mean compliance to 
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Artane of 138%, standard deviation of 33.0%. Upon the 
initial implementation of Elavil, during the final 
reversal phase, her mean compliance was at 99.8%, with a 
standard deviation of 13.5%. Following the introduction 
of the regimen card during Treatment A, a reversal to 
the vial demonstrated a marked increase in 
overmedicating, with a mean of 168.5%, standard 
deviation of 36.4%. This was close to reports of her 
past abusive behavior. The second reversal to the vial 
revealed a mean of 142.4%, standard deviation of 42.5%, 
in compliant behavior. For the final phase of the study 
the client indicated that her choice of packaging system 
was to be the vial for the remaining 2 weeks. At thi s 
point the medLc~tLon of Elavil was added to her medical 
regimen. Mean compliance to the Elavil regimen was at 
99.8%, standard deviation 13.5%. Her mean Artane level 
was 106%, standard deviation 14.5%, during this last 
phase. 
Results obtained for Client One indicated that both 
special packaging techniques had a positive effect on 
her overmedicating behavior with Artane in comparison to 
reversal Phases 1 and 2, but not in comparison to 
baseline. Slightly more appropriate levels of 
compliance were obtained while using the regimen card as 
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opposed to the 7-day baggie packaging system. During 
the final weeks of the study she chose to cont inue using 
the vial as opposed to the special packaging systems. 
·•· ArtMI« ·C>- Co9entln ·•· lmu>ramin(. 
Bast.l.in~ 
?.')~ · r II Vial reatment~ --'ITeat&ent fReversal 
+ Cards I ·. Bagqie~ Vial 
'·'''' 1 Verbal + I • I • 
· " 1 1 & Fee4bacli. \ feedbaCK 1 Feedb.iclt 
··r: r, + 1 GraphiCAl \ 
~ - ··' • I If ecdback • - • I 
~ I t. - •-•-• \ 
~ ?•Y ~\ /1 \ •-• 
~ 15•:• t l II '•-• I • 
D 1 I t tReversal 1 4 -• 
Q. I•>•:! \ f 1 1 Vial 
I I I + 
\ I I I fe.edbacl( 








Figure 6 Client Two was abusive with his Artane, 
and compliant with his Cogentin and Imipramine 
medications. The medications of Tofranil and Cogentin 
were added to his regimen during Reversal 3 . Axis x 
denotes the percentage of compliance; axis y designates 
the number of pill probe days . 
Client Two. The client was referred to the study by 
Community Re-entry Project due to his reported long term 
severe abusive behavior with his antiparkinson 
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medication of Artane (Figure 6). Baseline compliance to 
Artane was 173%, standard deviation of 85%, a figure 
considerably less than his past abusive overmedication 
behavior as described by his board and care home 
operator. Verbal and graphical feedback was introduced 
beginning the 2nd week of baseline and continued 
throughout the study. Upon the initiation of verbal and 
graphical feedback, his compliance level went to 210%. 
Overall levels of compliant behavior during 
treatment phases for the entire study revealed a mean of 
178%, with a standard deviation of 21.5%, while on 
Artane. Treatment A, using the regimen card packaging 
system produced 193.5% mean compliance, with a standard 
deviation of 45.6%, for Artane consumption, slightly 
better than verbal and graphical feedback alone. During 
the initiation of Treatment B, using the 7-day baggie 
packaging system, the client exhibiting 163% compliance, 
standard deviation of 31.2%. 
Reversal phases yielded a comprehensive mean level 
of compliance of 230.5%, standard deviation of 34%. 
Mean overall Tofranil compliance for the study was 133%, 
standard deviation 0%. Cogentin was added to the 
regimen in place of Artane during the final weeks of the 
study, which yielded a mean of 82%, standard deviation 
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of 35%. Reversal to the vial following the 
implementation of Treatment A using the regimen card 
packaging system, produced a dramatic degeneration in 
behavior of 270% mean compliance with a standard 
deviation of 92.4%, indicating that prior treatment with 
the regimen card had some effect on the client's 
compliance behavior. This gross increase in 
overmedication suggests the effectiveness of the regimen 
card packaging system in yielding more appropriate 
levels of consumption. Following a reversal to the vial 
after using the 7-day baggie packaging system as 
Treatment B, the client's behavior again slightly 
deteriorated to a mean of 211.5%, standard deviation of 
24.8%, suggesting that prior treatment with the 7-day 
baggie packaging system had some effect on his behavior. 
For the final phase of the study, the client chose 
to maintain use of the vial. His Artane compliance 
stayed at a mean of 210%, standard deviation of 0%, for 
the 1st week of this phase. Following a meeting with 
the client's psychiatrist to inform him of his patient's 
behavior during the study, his regimen was changed to 
Tofranil and Cogentin to aid him in appropriate 
medication compliant behavior. Cogentin was added in 
place of Artane because when it is abused, it produces 
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little or no sensation of feeling "high" as does Artane. 
His compliance was somewhat better with a mean level in 
compliance of 133%, standard deviation 0%, while on 
Tofranil. The implementation of Cogentin yielded the 
best overall level of compliance with a mean of 82%, 
standard deviation 35%. Results indicate that the 
special treatment packages aided in improving the 
client's medication compliance in comparison to reversal 
phases when the vial was used. 
Client Two demonstrated more appropriate levels of 
compliance to Artane during Treatment B while using the 
special packaging system of the 7-day baggie in 
comparison to reversal Phases 1 and 2 and the 
--implementation of- Treatment A using the regi~~ard 
packaging system. However, prior initiation of the 
regimen card may have contributed in cueing the client 
to reduce his intake of Artane. The client's best leve l 
of compliance occurred during the final reversal, while 
using the vial. This reduction in medication abuse 
might be attributed to a change in his medical regimen 
following a meeting with his psychiatrist. At this 
point the client was taken off Artane and placed on 
Cogentin and Imipramine. Cogentin was substituted for 
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Artane, due its ability to reduce parkinsonian-like 
symptoms without the "high" that Artane often produces. 
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Figure 7 Client Three was abusive with both Artane 
and Lithium medications. The medication of Lithium was 
added to his regimen during Treatment A. Axis x denotes 
the percentage of compliance; axis y designates the 
number of pill probe days. 
Client Three. The client was referred to the study 
by The University of the Pacific's Community Re-entery 
Project, due to his reported moderate long-term abusive 
behavior with his antiparkinson medication, Artane and 
his antipsychotic medication Lithium (Figure 7) . During 
baseline (Weeks 1-3), he exhibited a mean of 115% 
compliance to Artane, standard deviation of 29%, 
slightly better than his estimated level of compliance. 
During Weeks 2-3 he was presented with both graphical 
and verbal feedback, which continued throughout the 
remainder of the study. The initiation of verbal and 
graphical feedback appeared to improve his medication 
compliance behavior. 
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The overall mean level of compliant behavior for 
treatment phases for both medications was 103.%, 
standard deviation 12%. Comprehensive mean for all 
treatment phases while on Artane was 104.8%, standard 
deviation 10%. On Lithium mean compliance was 96.7%, 
standard deviation 21%, for all treatment phases. 
Compliance to Artane improved subsequently during 
Treatment A on the regimen card packaging system to 
100%, 0% standard deviation in comparison to baseline 
measures. At this time Lithium was added to the 
client's regimen, resulting in a mean compliance of 
88.6%, standard deviation 19.6%. Treatment B, using the 
7-day baggie packaging system, produced an improvement 
in mean compliance to 101.5%, standard deviation of 
2.8%, for both Artane and Lithium. Compliance for 
Artane during Treatment B was better, in comparison to 
the first reversal to the vial, by 40 points at 101.2%, 
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standard deviation 2 .5%. Lithium compliance during this 
phase improved to 101.7%, standard deviation 3.5%. For 
the final 2 weeks of the study the client chose to use 
the regimen card for Treatment C. Artane compliance 
during this final phase of treatment improved to a mean 
of 113%, standard deviation 15.6%; Lithium mean 
compliance was 110%, standard deviation 12.9%. These 
results suggest that the packaging system aided in 
appropriate medication compliant behavior for this 
individual client . 
Mean compliance for overall reversal phases for the 
entire study was 109%, standard deviation 46.9%, for 
both medications. The clients' mean compliant behavior 
was at 164%, standard deviation 58.9% for al l reversal 
phases on Artane . Reversals on Lithium demonstrated 
better mean compliance at 97%, standard deviation 21%. 
Reversal to the vial, following Treatment A using 
the regimen card packaging system, suggested that the 
regimen card had a positive effect on his behavior. He 
regressed in mean compliance with Artane to 141%, 
standard deviation 37%; Lithium mean compliance dropped 
below satisfactory levels to 76.8%, standard deviation 
31% . Following a return to the vial, after the 
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implementation of the 7-day baggie packaging system as 
Treatment B, Artane mean compliance deteriorated to 
187.5%, standard deviation 72%. Lithium mean compliance 
remained at an appropriate level of 102.75%, standard 
deviation 46.6%. In summary, Client Three maintained 
almost perfect levels of compliance for Artane while 
using both special packaging techniques in comparison to 
both baseline measures and reversal Phases 1 and 2. 
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Figure 8 Client Four was undercompliant with the 
medications of Mellaril and Lithium. Axis x denotes the 
percentage of compliance; axis y designates the number 
of pill probe days. 
Client Four. The client was referred to the study 
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by his Day Treatment Team Leader due to his reported 
long term moderate undercompliant behavior (Figure 8) . 
However, he terminated from the study before all 
treatment and reversal phases were implemented. For 
financial reasons, the client was moved into a board and 
care home, where medications were dispensed by the home 
operator . 
During baseline he achieved a combined mean for both 
medications of 68.5% compliance, with a standard 
deviation of 39.6%. Lithium compliance during baseline 
was at 50.8%, standard deviation 44.5%. Compliance with 
Mellaril during baseline was within appropriate levels 
for compliance at 86%, standard deviation 26.8%. These 
figures were not representative of his reported past 
undercompliant behavior as indicated by his Day 
Treatment Team Leader, who recalled it to be much worse. 
During Weeks 2-3, the presentation of verbal and 
graphical feedback was introduced. The initiation of 
feedback had some effect in reducing his undercompliant 
behavior, with Lithium as indicated, following Week 1 of 
baseline. However, the initiation of feedback yielded a 
severe decline in compliance with Mellaril. 
Treatment A, using the regimen card packaging 
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system, yielded a mean of 100%, with a standard 
deviation of 0%, for both Lithium and Mellaril. 
Following reversal to the vial his combined compliance 
behavior dropped 5 points to a mean of 95%, with a 
standard deviation of 11.8%. Mean compliance with 
Lithium during this reversal regressed 10 points to 90%, 
standard deviation 16%. Compliance with Mellaril 
remained at 100%, standard deviation 0%. The trend of 
the data prior to termination indicated that treatment 
with the regimen card aided in appropriate medication 
compliance behavior. Client Four responded positively 
to Treatment A using the regimen card and to the 
implementation of verbal and graphical feedback in 
comparison to baseline measures and the first reversal. 
The trend of data, while he participated in the study, 
strongly suggests that special packaging and feedback 
had a positive effect on improving his compliance. -
I 66 ·-·-·-· ' -·-·-· I ·-·----· ·-·-·__... ·--·-· 






\ • .. 
• 
i'rea.t.ment Al ReversaJ. i 
Saqq1o Vial 
Treatment e I ~ever.sal2 




Figure 9. Client Five was undercompliant with the 
medication of Prolixin. Axis x denotes the percentage 
of compliance; axis y designates the number of pill 
probe days. 
Client Five. The client was referred to the study 
by his Day Treatment Team Leader and pharmacist due to 
his reported moderate, short term, undercompliant 
behavior with his antipsychot i c medication of Prolixin 
(Figure 9) . During baseline his mean compliance was 
79.8%, with a standard deviation of 37.9%. Within Weeks 
3-4 of .baseline, he was presented with verbal and 
graphical feedback which continued throughout the 
remainder of the study. The initiation of feedback 
appeared to have a severe negative effect in that his 
compliance behavior dropped to near 0% until the 
introduction of Treatment A, where he achieved a 
compliance average of 100%, standard deviation of 0 %, 
for all treatment phases and reversal phases. In 
Treatment A, using the 7-day baggie special packaging 
system, his mean compliance was 100% , with a standard 
deviation of 0%. Following a reversal to the vial, he 
continued to maintain a mean of 100% compliance , 
s tandard deviation of 0 %, and continued t his pattern 
throughout al l treatment and reversal phases. The 
c lient 's behavior was 100% compliance throughout all 
phases of the study except for the last two probes 
during base line. It is difficult to conclude anything 
regarding treatment from this subject's behavior. 
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Figure 10 Client Six was undercompliant with the 
medications of Artane and Loxitane. Axis x denotes the 
percentage of compliance; axis y desigantes the number 
of pill probe days. 
Client Six. The client was referred to the study by 
his psychiatrist and pharmacist due to his repeated l ong 
term, severe undercompliant behavior with his 
antiparkinson medication of Artane and his antipsychotic 
medication of Loxitane (Figure 10) . Baseline compliance 
was at a mean leve l of 90%, standard deviation o f 61%, 
for the 4-week period for both medications combined. 
For Loxitane his mean compliance level was 63%, standard 
deviation 46%. Baseline mean Artane levels were above 
appropriate compliance at 114.5%, standard deviation 
69.9%. These figures were not representative of his 
past undercompliant behavior as indicated by his 
psychiatrist and pharmacist. During Weeks 3-4, he was 
presented with ve rbal and graphical feedback, which 
continued throughout the study. The introduction of 
feedback had a positive effect on his compliance 
behavior in comparison to baseline in Weeks 1 and 2. 
The mean overall level of compliance during the 
treatment phases was 95%, with a standard deviation of 
10.6% for both medications. Loxitane compliance for all 
treatment phases was 94%, standard deviation 11%. His 
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mean compliance for Artane in all treatment phases was 
95.7%, standard deviation 10.6%. During Treatment A, 
using the 7-day baggie packaging system, mean compliance 
was 87% , with a standard deviation of 15%, for both 
medications, reflecting little difference between 
baseline and the first introduction of treatment. 
Individual compliance for Loxitane, however, improved by 
24 points to a mean of 87% , standard deviation 16%. 
Medication behavior with Artane improved to 87% , 
standard deviation of 16%. The implementation of 
Treatment B, using the regimen card packaging system, 
produced an improvement to 100%, standard deviation of 
0%, in medication compliance for both Loxitane and 
Artane . The client chose the special packaging 
technique of the regimen card for the final weeks of the 
study indicated as Treatment C. His mean compliance was 
97.8% , with a standard deviation of 6%, for both 
Loxitane and Artane. Mean compliance with Loxitane 
during this phase remained within appropriate levels at 
95.7%, standard deviation 8.5%. Compliance with Artane 
remained consistent at 100%, standard deviation 0% . 
Overall , the client appeared to benefit slightly by 
using the regimen card packaging system as opposed to 
the vial and 7-day baggie systems. 
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The client achieved a mean of 96%, with a standard 
deviation of 7.7%, for all reversal phases for both 
medications. Compliance on Loxitane for all reversal 
phases remained at an appropriate mean level of 100%, 
standard deviation 0%. Artane compliance for all 
reversal phases also remained at appropriate mean levels 
with 92%, standard deviation 9.6%. Following reversal 
to the vial after the introduction of the 7-day baggie 
packaging system during Treatment A, his mean compliance 
for both medications was 99%, standard deviation of 
2.8%. Loxitane mean compliance at this time improved to 
100%, standard deviation 0%, and mean compliance to 
Artane improved by 11 points to 98%, standard deviation 
4%. Upon the second reversal to the vial, after using 
the regimen card packaging system, his mean compliant 
behavior regressed 7 points to 93%, with a standard 
dev iat ion of 10%, for bot h medications. His compliance 
with Loxitane maintained at 100%, standard deviation 0%, 
but Artane compliance deteriorated to 87%, standard 
deviation of 10.3%. 
Client Six demonstrated a perfect level of 
compliance behavior for both of his undercompliant 
medications while using the regimen card packaging 
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system for Treatment B. Prior to this phase his 
compliance to both regimens varied during baseline. 
Upon the implementation of verbal and graphical feedback 
his compliance to both medications reached more 
appropriate levels of consumption. The data for this 
client suggest that the presentation of feedback helped 
to achieve more appropriate consumption of both 
medications in his regimen. 
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Figure 11 Client Seven was abusive with Artane, and 
undercompliant with Navane and Lithium medications. The 
medication of Navane was added to her regimen during 
Treatment B, and Lithium during Reversal 2. Axis x 
denotes the percentage of compliance; axis y designates 
the number of pill probe days. 
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Client Seven. The client was referred to the study 
due to moderate, long-term, undercompliant and abusive 
behavior as reported by her pharmacist and psychiatrist 
(Figure 11) . During the 4 weeks of baseline she 
achieved a mean of 94.8%, standard deviation of 14%, 
while on Elavil. This figure was not representative of 
her over-and undermedicating behavior as indicated by 
both her pharmacist and psychiatrist. During Weeks 3-4 
she was presented with both verbal and graphical 
feedback that was continued for the duration of the 
study. The initiation of feedback had a positive effect 
on her medication compliance behavior, as exhibited in 
the trend of the data beginning in Week 3 of baseline. 
Her mean levels of compliance during all treatment 
phases with all three medications for the study yielded 
98.7% , standard deviation of 12%. Mean compliance with 
Elavil for all treatment phases was within appropriate 
levels at 96 .7%, standard deviation 13%. Mean 
compliance with Navane, which was implemented during 
Treatment B, was 100% , standard deviation 0%. Treatment 
A, using the 7-day baggie packaging system, revealed a 
mean of 107.5%,with a standard deviation of 15%. When 
placed on Treatment B, the regimen card packaging 
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system, the client obtained a mean level of 90% 
compliance, with a standard deviation of 22%, for the 
medications of Elavil and Navane. Navane was added to 
her regimen at this time by her psychiatrist. 
Individual levels of compliance obtained for Elavil 
revealed a mean of 87.5%, standard deviation 25%; mean 
compliance with Navane during Treatment B was 100%, 
standard deviation 0%. 
For reversal phases throughout the study the client 
obtained a mean compliance level of 87.8%, with a 
standard deviation of 21 .5%, for all three medications 
combined. Mean compliance for Elavil for all reversals 
was 83.6%, standard deviation 30 .9%. Complaint behavior 
with Navane also revealed an appropriate mean level at 
83%, standard deviation 21% . Her mean compliance with 
Lithium for both reversal phases (reversals Phases 2 and 
3) was 87%, standard deviation 18%. Following reversal 
to the vial after the implementation of the 7-day baggie 
packaging system during Treatment A, mean compliance was 
100%, with a standard deviation of 0%, for Elavil 
consumption. Upon reversal back to the vial following 
the regimen card special packaging system, her 
medication regimen was altered a second time with the 
inclusion of Lithium. Mean combined compliance with all 
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three medications during the second reversal phase 
yielded 100.6%, with a standard deviation of 12%. Her 
mean adherence to Elavil was 103%, standard deviation 
6%, still remaining within appropriate levels of 
compliance. Mean compliance to Navane during the second 
reversal was 98.5%, standard deviation 19.6%, a 
regression of 1.5 percentage points. Mean compliance 
with Lithium was 100%, standard deviation 0%. 
For the remaining 2 weeks of the study she chose the 
vial over the special packaging techniques of the 
regimen card and 7-day baggies. The client's mean level 
of compliance for this phase for all three medications 
was 63%, with a standard deviation of 33%. Mean 
~mpliance to Elavil revealed a mean of 48%, standard 
deviation of 28%, a 55-point deterioration in compliance 
from the preceding phase of the study. Adherence to 
Navane also regressed 31 points from the preceding phase 
to 67 .5%, standard deviation 42.9% . Her mean compliance 
to Lithium was 74%, standard deviation 30.5%, a 26-point 
deterioration from the preceding phase. 
This client's most appropriate level of medication 
compliance was achieved when using the vial, in the 
first reversal phase. However, this trend of 
appropriate compliance was set during Treatment A with 
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the baggies, suggesting that special packaging had a 
positive carry over effect during the first reversal 
phase. Her medication compliance behavior was at its 
worst during the last phase of treatment. This 
deterioration in compliance may be attribut able in part 
to the confusion caused by the addition of two new 
medications to her medical regimen . 
In summary, r esults for Client Seven i ndicated that 
she obtained a perfect level of compliance during the 
first reversal to the vial. Baseline measures indicated 
an initial fluctuation of both abuse and undercompliance 
for her previously defined abusive behavior o f Elavil. 
The implementation of verbal and graphical feedback 
produced more appropriate levels of medicat ion 
consumption which was maintained throughout most of 
study with the exception of the third reversal to t he 
v ial. Dur ing the t hird reversal Navane and Lithi um we re 
added to her medical regimen, perhaps making c ompliance 
more di f ficult for her. 
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Figure 12 Client Eight was abusive with Artane, and 
undercompliant with Loxitane. Axis x denotes t he 
percentage of compliance; axis y designates the number 
of pill probe days. 
Client Eight. The client was referred to the study 
by his pharmacist and psychiatrist who reported severe, 
long-term abusive and undercompliant behavior with his 
antipsychotic medication of Loxitane and his 
antiparkinson medication of Artane (Figure 12) . During 
baseline his mean level of compliance was 108%, with a 
standard deviation of 23%, for Loxitane and Artane 
combined, a figure not representative of the reported 
severity of his compliant behavior. His compliance with 
Loxitane during baseline was 100%, standard devi ation 
0%. Compliance to Artane during baseline exceeded 
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appropriate levels , with a mean of 117.6%, standard 
deviation 32% . Within Weeks 3-4, he was presented with 
verbal and graphical feedback , which continued 
throughout the duration of the study. The introduction 
of feedback had no effect on his compliance behavior. 
The Client's overall mean for treatment phases 
throughout the study was 132 % compliance , with a 
standard deviation of of 47.6%, for the combination of 
Loxitane and Artane. Overall mean for Treatment Phases 
A and B was 132%, standard deviation of 47.6%, for both 
medications . Mean compliance for Loxitane for all 
treatment phases yielded 96% , standard deviation 23%. 
Mean consumption for Artane in all treatment phases was 
~yond appropriate levels_Qf_ compliance with 148 %, 
standard deviation 1 . 1%. Mean compliance for Treatment 
A using the 7-day baggie packaging system, for both 
Loxitane and Artane was 114%, standard deviation of 
51.6%, an 8-point deterioration in his behavior . During 
Treatment A on Loxitane his mean compliance was at 
79 . 5%, standard deviation 39%, a 20.5 point 
deterioration in compliant behavior. Mean compliance to 
Artane during Treatment A deteriorated to 149%, standard 
deviation 23% , a 31.4 point change in comparison to 
baseline . Under Treatment B, using the regimen card 
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packaging system, mean Loxitane compliance deteriorated 
to 112.5%, standard deviation 14%, while mean Artane 
compliance improved by 9.5 percentage points to 147.5%, 
with a standard deviation of 8.6%. Mean combined 
compliance for both medications during this phase was 
130%, standard deviation of 21.7%. 
Reversal Phases 1 through 3 produced a comprehensive 
mean of 139%, standard deviation of 12.30, for both 
medications. Loxitane for both reversals had a mean of 
98.9%, standard deviation 1.5%. Compliance with Artane 
for all reversals exceeded appropriate compliance at 
184%, standard deviation 25%. Upon reversal to the vial 
following Treatment A using the 7-day baggie packaging 
system, adherence to Loxitane improved to 100%, standard 
deviation 0%, while compliance to Artane deteriorated 
further to 157%, with a standard deviation of 49.7%. 
During the second reversal, mean Loxitane compliance 
improved to 95.%, standard deviation 8.5%. Mean 
compliance to Artane again exceeded appropriate levels 
at 177.5%, standard deviation 26%. For the final weeks 
of the study the client chose to use the vial as opposed 
to the special packaging techniques of the regimen card 
and the 7-day baggie. His compliant behavior 
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deteriorated to 152.75%, with a standard deviation of 
62% , for both medications. For Loxitane compliance, he 
improved to a mean of 100%, standard deviation 0%. Mean 
compliance to Artane was at its worst level during this 
phase with a severe degeneration to 202.5%, standard 
deviation 39 . 8% . 
The client's compliance to Artane deteriorated in 
each reversal; where his compliance to Loxitane 
deteriorated during each treatment phase, suggesting 
that special packaging had a mixed effect on compliance. 
Undercompliant Behavior 
In review of Group I (those clients who received the 
card packaging system first) clients who were 
undercompliant in their medical regimens, only one 
client, Client 4, was undercompliant with two 
medications (Table 3). This client's level of 
medication compliance is described in detail in the 
preceding pages under Client 4. 
Group II (received the 7-day baggies first) 
consisted of 3 clients who were undercompliant in their 
medical regimens with a total of six medications (Table 
4). During the 4 weeks of baseline these clients 
obtained a mean level of 89%, standard deviation 22.6%, 
in compliant behavior. Beginning at Week 3, verbal and 
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graphical feedback was implemented. It was difficult to 
determine the effect of feedback, however, it is 
hypothesized due to the trend in data for this group 
that there was little effect. The baseline levels of 
compliance was above reported levels of undercompliant 
behavior by referring staff. Upon the initiation of 
Treatment A , the 7-day baggie packaging system, 
compliant behavior maintained at a mean of 88% , standard 
deviation 8.5%. During the first reversal, mean 
compliant behavior improved to 99.5%, standard deviation 
1%. Upon the initiation of the regimen card special 
packaging system for Treatment B, mean compliance for 
this group reached 100%, standard deviation of 0%. This 
figure was the best level of compliance for the entire 
study; following this phase compliance slightly dropped. 
During the second reversal to the vial mean compliance 
slipped to 96 .7%, standard deviation 5.5%. During the 
final phase of the study, two of the clients chose the 
vial and one client chose the card packaging system to 
obtain their medication. Those clients on the vial 
obtained 80.5%, standard deviation of 17%, and the one 
client on the card packaging system obtained 97.8% with 
a standard deviation of 6%. Overall reversal phases for 
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undercompliant medications in Group II showed a mean of 
92%, standard deviation of 10%. The overall phases mean 
compliance for the group was 95%, with a standard 
deviation of 6%. 
Medication Abusive Behavior 
There were three clients abusing a total of four 
medications in Group I (Table 3) . Basel ine measures 
revealed a mean of 94% , standard deviation of 8 . 48%, a 
figure not representative of the level of abuse reported 
by referring parties. During Week 2, verbal and 
graphical feedback was initiated. The trend of the data 
for this group throughout the study suggests that 
feedback had l ittle or no effect on clients' self-
medicating behavior. UEon the initiation of Treatment 
A, the regimen card packaging system, compliance 
behavior regressed to 125.9%, standard deviation 47 . 1%, 
thereby exceeding appropriate levels of compliance. 
Reversal to the vial revealed more expected levels of 
medication abuse with a mean of 164.1%, standard 
deviation of 80%, a difference of 70 points in 
comparison to baseline measures. Upon the initiation of 
Treatment B, using the 7-day baggie packaging system, 
clients improved in their level of compliance achieving 
mean of 123.5%, standard deviation of 29%. A second 
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reversal back to the vial demonstrated another 
regression of compliance of 161%, standard deviation 
48%. For the final phase of the study 2 out of the 3 
clients chose to remain on the vial, and 1 chose the 
special packaging device of the regimen card. The 
results during this phase revealed a mean level of 
compliance for those choosing to remain on the vial t o 
be 158%, standard deviation of 73%, and 111. 5%, with a 
standard deviation of 2%, for the 1 client who chose t he 
regimen card for Treatment C. The overall level of 
compliance for the reversal phases was 161 .%, with a 
standard deviation of 3%, in comparison to overall 
treatment phases of 120%, with a standard deviation of 
7%. These figures suggest the strong effects of __ special 
packaging in comparison to the vial in reducing 
medication abuse in overmedicating patients. 
Abusive behavior for Group II consisted of 2 clients 
overmedicating with a total of three medications (Table 
4). Mean baseline compliance was 105% , standard 
deviation .17%, a figure that was not representative of 
the actual level of abuse reported by referring 
agencies. Implementation of Treatment A, the 7-day 
baggie packaging system, brought about a deteri orat i on 
of appropriate medication consumption to 12 7 .5%, 
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standard deviation 30%. Reversal to the vial yielded 
compliance of 128.5%, standard deviation of 40%. The 
implementation of the regimen card special packaging 
system for Treatment B improved the medication 
compliance mean to 117.5%, standard deviation 42%. Upon 
reversal to the vial , compliance deteriorated again to a 
mean of 140%, standard devi ation 52%. For the final 
phase of the study, both clients preferred to remain on 
the vial as opposed to the special packaging systems 
offered. Mean compliance again exceeded the appropriate 
levels of consumption at 11 6 . 8% , standard deviation 
78. 6% . Overall levels of compliance during the reversal 
phases for this group yielded 128%, standard deviation 
11 .6%, in compliant behavior. Overall level of 
compliance du~ing treatment phases was 122.5%, standard 
deviation 7%, a 6- point improvement in compliant 
behavior. These results suggest that the implementation 
of the special packaging produced more appropriate 
levels of medication compliance in comparison to 
reversal Phases 1 and 2, but not baseline. The best 
level of compliance occurred during baseline and 
Treatment B with the implementation of the regimen card . 
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Table 3 
Undercompliant and Abusive Data For Group I 
Undercompliant Medication Only On Group I: Receivin~ Cards First 
~ Condition M Cin percenta&es) SIL Overall M & SD 
1-3 Baseline 68.4% 24.8% For Reversals 1&2 
M = none, SD = none 
4-6 Treatment A 100.0% 0.% For Treatment Phase A 
M =100%,Sll =0% 
7-8 Reversal 1 95.% 7.07% 
9-10 TreatmentB none none N=1 (Client 4)) 
11-12 Reversal 2 none none 
13-14 Treatment C/ none none 
(Reversal 3) 
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Abusive Medication Only On Group 1: Recejyin~ Cards First 
Week Condition M Cin percentages) SlL_ Overall M & SD 
1-3 Baseline 94.% 8.48% For Reversals 1&2 
M = 161.%, Sl2 = 3% 
4-6 Treatment A 
7-8 Reversal! 
9-10 Treatment B 
11-12 Reversal 2 
13-14 Treatment C 
(cards) or 













47.1% For Treatment Phases 
M =120%,SD= 7% 
N=3 (Clients 1, 2, 3) 
Undercompliant and Abusive Data For Group II 
Undercompliant Medication Only In Group II: Receiving Baggies First 
Week Condition M Cin percentages) .sJ2. Overall M & SD 
1-4 Baseline 89.% 22.6% For Reversals 
M = 92%, SD = 10% 
5-7 Treatment A 
8-10 Reversal 1 
11-13 Treatment B 
14-16 Reversal 2 
17-19 Treatment C 
(cards) or 








85.% For Treatment 
M = 96.0%, S12 = 6.3% 
1.% 




Abusive Medication Only In Group II: Receiving Baggies First 
Week Condition M (in percentages) SD Overall M & SD 
1-4 Baseline 105.% 17.% For Reversals 
M = 128%, SD 11.6% 
4-7 Treatment A 127.5% 30.% For Treatment · 
M = 122.5%, .s..Q =7% 
8-10 Reversal 1 128.5% 40.% 
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11-13 Treaunent B 117.5% 42.% N=2 (Clients 7, 8) 
14-16 Reversal 2 140.% 52.% 
17-19 Reversal 3 116.8 78.6% 
Discussion 
The results obtained in the present study support 
the previous findings of Demetral et al. (1978) that the 
use of special packaging in comparison to baseline 
measures and reversals with the vial enhances medication 
compliance among noncompliant psychiatric outpatients. 
Medication Abuse 
Abusive clients within Group I (who received the 
regimen card system for the first treatment phase) 
demonstrated more appropriate levels of compliance while 
using the special packaging techniques in comparison to 
reversals while using the vial. Treatment B, while 
using the 7-day baggie packaging system, yielded 
slightly better results than that of the regimen card 
packaging system by 2.4 percentage points. Starting 
with the regimen cards for Treatment A may have had an 
influence in setting the appropriate trend in compliance 
for the baggies. Dramatic differences were found 
between Treatment A and B Phases in comparison to 
reversal Phases 1, 2, and 3. 
Abusive clients within Group II demonstrated more 
appropriate levels of compliance during Treatment B, 
while using the regimen card special packaging system, 
in comparison to Treatment A, using the 7-day baggie 
system, and in reversal Phases 1, 2, and 3. 
Undercompliance 
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Within Group I (those who received the card system 
first), there was 1 client who demonstrated appropriate 
compliance behavior following the initiation of the 
regimen card special packaging technique. Upon the 
initiation of the first reversal to the vial there was a 
slight regression in compliance. It is hypothesized 
that the level of compliance obtained during the first 
treatment phase would have continued throughout the 
study if the client had continued to participate in the 
program . 
Undercompliant clients in Group II (who received the 
baggie system first) demonstrated a trend which s uggests 
the implementation of the regimen card special packaging 
system, during Treatment B, to produced the best level 
of compliance compared to baseline, reversal phases, and 
Treatment A using the 7-day baggies . Within the final 
phase of the study 1 client chose to continue using the 
regimen card package, while the remaining 3 clients 
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chose the vial. Medication compliance during this phase 
was within appropriate levels of consumption, but it did 
not yield the perfect compliance obtained while these 
clients were using the regimen card packaging system . 
Benefits of Special Packaging 
As hypothesized, medication compliance with the 
regimen card packaging system yield the best compliance 
levels for undercompliant clients, most likely due to 
the provision of visual feedback to the clients . Many 
undercompliant clients are forgetful as to the time they 
are to consume their medications and the number of pills 
to be taken. With the implementation of the regimen 
card, these clients were able to detect easily when they 
were to consume their medications; the card also 
provided them with information regarding how many pills 
they had or had not taken. The more appropriate level s 
of consumption obtained with abusive clients when using 
the regimen card may also be attributed to the card's 
visual feedback feature . The information the card 
provided as to the number of pills they had taken during 
a particular day, as well as over a week's period, may 
have limited clients' level of abuse through providing 
concrete information as to their degree of medication 
abuse . 
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Overall, the results indicated that regardless of 
which special packaging system was introduced first as 
Treatment A, the regimen card packaging system yielded 
the most appropriate levels of medication compliance for 
those clients who benefitted from the special packaging 
techniques. Differences were found between the effects 
of the two special packges depending on which system the 
clients were started on . In review of Groups I and II 
when the sequencing of treatment phases was the cards 
followed by the baggies as in Group I, mean compliance 
levels for overmedicators was 125.9% in comparison to 
those in Group II who received the baggies first 
obtaining a mean 127.5% compliance. Undercompliers in 
Group I obtained a mean of 100% compliance when 
beginning on the card and 88% for Group II receiving the 
baggies first. This indicates that the use of regimen 
card, when introduced during the first phase of 
treatment, yields better compliance in comparison to 
starting with the baggies. Perhaps it was easier to see 
the separate doses to be taken when using the card, and 
that this helped to set a trend for more appropriate 
levels when using the baggies. 
91 
Casual observations suggest that most clients who 
abuse their medication were unaware as to the degree 
they were overmedicating. Three abusive clients 
(Clients 2, 3, and 8) revealed that their mode of 
consuming medications, prior to the implementation of 
the study, was to hold up a medication vial to their 
mouth and then taking a swallow as if the v i al were a 
glass containing liquid. One abusive client (Client 2) 
confessed that during the times he ran out of Artane 
(during the first 2 days of the week), he would make 
street purchases for more than $1.00 per pill to relieve 
his Parkinsonian-like symptomatology . (Apparently the 
overmedicating during the beginning of the week was to 
achieve a 'high' for a couple of days.) Two 
undercompliant clients (Clients 6 and 7) and one 
overcompliant client (Client 3) revealed to me that due 
to the number of different pills in their weekly regimen 
they had felt confused, and at times it was very 
difficult to get the prescription instructions straight. 
Implementation of the special packaging techniques 
presented clients with hard to ignore, yet easy to see 
evidence of the seriousness of their overmedicating 
behavior. Two clients preferred the visual aid 
advantage of the regimen card system over the vial and 
requested to be a part of the Community Re-entery 
Projects program in order to continue use with this 
packaging device. 
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However, more clients preferred the vial, as opposed 
to the special packaging of their medications, when 
given the choice. Questioning revealed that some 
abusive clients (Clients 1,2, and 8) did not like 
knowing the degree of their abusive behavior. They were 
generally unaware of the amount of medication they were 
ingesting at the beginning of a week until using the 
special packaging techniques. 
The degree of noncompliance exhibited by the clients 
in this study took their psychiatrists by surprise. 
Most of them were completely unaware of the degree of 
over-and undermedicating in which clients were engaging. 
The majority of these psychiatrists conveyed to me their 
plans to change the regimen of their clients' medication 
and/or place them on 1-day-medication-compliance 
following the termination of the study or during its 
final phase. Two psychiatrists inquired of their 
clients' best level of compliance during the study. 
Upon learning that the best levels obtained were when 
clients were using special packaging techniques, they 
further inquired how they might be able to maintain 
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their clients on one of the packaging systems following 
termination of the study. 
Problems Associated With the Study 
Referring agencies indicated that the clients in 
this study were much more noncompliant than the initial 
baseline revealed the clients to be. While complinance 
during reversals seemed to be more congruent with the 
referrals. This is strong evidence for reactivity in 
the initial baseline. By the time of the first reversal 
within the study , clients may have felt more comfortable 
with the study and the pill counts, and thereby fell 
back into more "natural" levels of consumption of 
medications, as opposed to during baseline. Longer 
baseline and treatment phases should have been 
implemented in order to alleviate this problem. 
Verbal and graphical feedback had little effect on 
compliance, and its contribution to the study was 
difficult to determine. Longer phases with verbal and 
graphical feedback implemented without the inclusion of 
packaging could have been used in order to note the 
benefits of this variable in the study. 
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Future Research Interventions 
Recommendations for future research include changes 
in the regimen card, longer intervals for treatment 
phases, and longer phases of baseline. 
Some modifications of the regimen card packaging 
system could enhance compliance. The card might be 
designed to fit into the back pocket, coat pocket, or 
purse of a client to enable them to carry the packaging 
system with them wherever they go. This would be more 
convenient than folding it in half, or bending the 
system in such a way as to cover the prescription 
instructions , which was noted during the present study. 
Investigating special packaging effects with those 
who abuse their medications provides more reliabl e pill 
count data than with those who undermedicate, since a 
pill taken is a pill missing . Overmedicators might be 
tempted to take to the streets to purchase additional 
pills; however, it would be difficult to time the 
consumption of street versus card pills in such a way as 
to simulate appropriate compliance. For instance, the 
client would have to purchase a large number of pills on 
the street for a price, hide them, and dip into this or 
her stash throughout the week or engage in daily buying 
of pills so as not to disrupt the special unit dose 
packaged medications held within the regimen card. 
Further, most clients do not have enough funds to 
purchase large amounts of additional medications and 
rarely can spare the price and bother of buying 
additional daily pills. 
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The regimen card packaging system has many 
advantages over the standard medication vial and the 7-
day baggies. Its design further aids clients in 
complying as directed and provides them with immediate 
feedback as to their level of compliance on a given day. 
The vial provides no feedback as to the number of pills 
taken or not taken without emptying the entire contents 
of the vial and counting each pill. This technique to 
check compliance is very tedious, especially if clients 
need to check whether or not they have taken their pill 
several times a day, and with several medications in 
their regimen. The regimen card's visual display of 
pills was also found to be more helpful to clients in 
comparison to the baggie package. Clients were able to 
open their card for a particular day and immediately 
note their level of compliance. Using the baggies, 
clients needed to empty the contents of their bag for a 
particular day, and then review each additional bag 
inside labeled for the time frames of consumption, and 
check their compliance. 
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Thus the implementation of special packaging using 
the regimen card system has significant benefits. The 
present study has demonstrated the regimen card's 
advantages in yielding more appropriate compliance 
levels among both under-and overmedicators. The 
implementation of this packaging system has particular 
importance with abusive medication compliers in helping 
physicians give additional help in the f orm of visual 
feedback to their outpatients in proper self-medication 
behavior, thereby decreasing recidivism and 
rehospitalization rates. In addition, the regimen card 
can help in reducing the number of visits abusive 
clients make to their pharmacist in which to obtain more 
medication on daily or weekly bases, and cut down on the 
frequency of purchasing additional medications on the 
street for a price. Overall, the regimen card has 
significant beneficial effects for the abusive client 
and would be worth further investigation of its 
effectiveness with other drug abusing populations. 
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Appendix A 




My name is Nicole Miller. I am a graduate student 
at the University of the Pacific, working on my master's 
degree in Applied Behavior Analysis Psychology. 
At present I am working on my thesis project. I am 
studying the effects of special packaging techniques on 
medication compliance with chronic outpatients 
affiliated with the mental health system. My hypothesis 
is that, with the aid of special packaging techniques, 
compliance behavior will increase. 
I am writing to you in hopes that you can aid me in 
obtaining outpatients for this research. I am looking 
for outpatients who are suspected of having problems 
with complying to their medication regimen(s). Failure 
in compliance, for the purpose of the present study, 
consists of a patient who has failed to comply with his 
or her prescribed daily regimen of medication by 
consuming too little or too much of his or her 
medication regimen(s) during the time frames designat ed 
by his or her prescribing physician. The present study 
will begin in April and terminate in August. 
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I would appreciate your assistance in referring 
clients who fit the above description and who you feel 
would most benefit from such a program. I will be 
calling you in the near future to arrange a time in 
which we can meet to demonstrate the special packaging 
techniques that will be used, and to further explain the 






With sincere thanks, 
Nicole Miller 
Appendix B 
Referral card/consent form 
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Medication Cornoliance Program 




Initial Meeting Date : 
Referral Source: 
Doctor(s) : 
Client Availability: Days : __________ _ 
Ti me : -----------
Alternative Sources o:t Contact: 
Client Diagnosis: 
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!de d . Como . Coorainator Info . 
I Assigned Staff : 
Client Accept Date : I 
Client Te rminate Date : I 
Reason for Termination: I 
Other Info. 




Request for doctor's assistance form 
~ ---
Dear Dr. -------------------
Thank you for referring clients to the Medication 
Compliance study. I have obtained a random list of 
clients for my research. One of your clients, (or 
several of your clients), , has/have been 
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chosen to participate. Each client's medication will be 
filled at the Mental Health Center's pharmacy and 
packaged in the special packaging systems of the regimen 
card and the 7-day baggie system by the University of 
the Pacific's pharmacy intern. 
The packaging systems mentioned above involve 
packaging 7 days of medication into unit dose plastic 
containers. The medications divided into 7 daily bags 
or cards, and medication regimens are separated by the 
time of day. This system is designed to provide the 
client with direct feedback concerning the type of 
medication and time of day it is to be taken, thereby 
alleviating the problems with under-and overmedicators. 
If you have any questions or concerns , please do not 
hesitate to contact me. 
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In order for to participate in the -------------
Medication Compliance study, I need you to read and sign 




I give my permission for to -------------------
participate in the Medication Compliance study, and to 
have his or her medication(s) packaged in the special 
I 
techniques of the regimen card and 7-day baggie, at the 
Mental Health Center's pharmacy, and packaged by the 
f 







Consent for participation 
112 
1. I give my physician permission to call the 
medications prescribed for my use to the San Joaquin 
Mental Health Center's pharmacy. I a lso give San 
Joaquin Mental Health Center's pharmacy and their staff 
permission to package the medications in the special 
packaging systems of the regimen card, the 7-day baggie, 
and in the medication vial, which have been expl ained to 
me . The experimenter will then return the medication to 
me at the previously arranged dates and times. 
2 . In addition , I agree to let the exper imenter 
have access to my outpatient personal fi le in which to 
aid her in my medication treatment. 
3. I also agree to part i cipate in the medication 
packaging program for the duration of the study, a 
designated time frame of 4 months (April through July), 
and to comply with the experimenter to the best of my 
ability . 
4. I understand that the medications from sever al 
prescriptions will b e packaged together with each 
individual dose packaged in a presealed container . I 
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also understand that the system is not child resistant 
and to keep it out of children's reach at all times. 
The above procedure has been thoroughly explained to me 
and any questions I may have concerning this procedure 
have been answered to my complete satisfaction. 
Experimenter's Signature: --------------- Date: -----------
Client's Signature: Date: -------------------- -----------
Client's Address & Phone No.: -----------------------------
Best times to be reached: ----------------------------------
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Appendix E 
Individual Data For Groups 1 and 2 
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Individual Data For Group I 
Client One: Individual Raw Data (Group D 
Condition 
Baseline 
Medication(s) M (in percentage) .s.IL Overall M & SD 
Artane M= 104.4% 16.4% For Reversals 
Treatment A Artane M= 121.8% 
Reversal 1 Artane M= 168.0% 
Treatment B Artane M= 128% 
Reversal 2 Artane M= 142.4% 
Reversal 3 Combined M= 103.0% 
Artane M= 106.0% 
Elavil M= 99.8% 
M..= 138%, Sl2 = 33.0% 
13.3% For Treatments A&B 
M =124.9%, SD=4% 
36.8% 
16.2 Artane M = 119%, 
SD = 16.5% 





Client Two: Individual Raw Data CGroup J) 
Baseline Artane M= 173.0% 
Treatment A Artane M= 193.5% 
Reversal 1 Artane M= 270.0% 
Treatment B Artane M= 163.0% 
Reversa13 Combined M= 141.6% 
Artane M= 210.0%, 
Tofranil M= 133.0%, 
Cog en tin M= 82.0% ' 
Client Three: Individual Raw Data (Group D 
Baseline Artane M= 115.0% 
. 1 1 6 
85.% For Reversal M= 148.5%, 
S.I2=75 
45.6% Artane M = 230.5%, 
S.I2=34% 







Cogentin M = 82%, 
SD = 35% 
For Treatment A&B- -
M=178%,SD=21.5% 





Treattnent A Combined 
Artane 
Lithium 
Reversal ! Combined 
Artane 
Lithium 






















Client Four: Individual Raw Data In Group I 
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12.8% Artane M = 164%, 
SD = 58.9% 
0 .% Lithium M = 97.%, 
19.6% SD = 21% 












Artane M = 104.8%, 
SD = 10% 
Lithium M = 96.7%, 
SD = 21% 







Treatment A Combined M= 100% 0.% 
Lithium M= 100% 0.% 
Mellaril M= 100% 0.% 






Treatment B (Terminated from study) 




Individual Data For Group II 
Client Five: Individual Raw Data In Group TI 
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Condition Medication(s) M Cin percenta~es) .s.IL Qverall M &SD 
Baseline Prolixin 79.8% 37.9% For Reversals M = 100%, 
Treannent A Prolixin 100.% 0.% 
Sl2=0% 
For Treattnent A&B 
M =100%,Sl2 =0% 
Reversal 1 Prolix.in 100.% 
Treaunent B Prolix.in 100.% 
Reversal 2 Prolixin 100.% 
Reversal 3 Prolixin 100% 




Treaunent A Combined 
Lox.itane 
Artane 


























For Reversals M = 96%, 
SD =7.7% 





For Treaunents ABC 
M=95%,S12=10.6% 
Loxitane M=94%, 
SD = 1%1 
Artane=M=95.7%, 
SD=10.6% 
Treatment B Combined 
Loxitane 
Artane 
Reversal 2 Combined 
Loxitane 
Artane 























Baseline Elavil 94.8% 14.% For Reversals 87 .8%, 
.su = 21.5% 
Treatment A Elavil 107.5% 
Reversal 1 Elavil 100% 
15.% Elavil M= 83.6%, 
SJ2 = 30.9% 
0.% Navane M = 83%, 
SJ2=21% 
Treatment B Combined 
Elavil 
Navane 



































Elavil M =96.7%, 
SJ2=13 
Navane M = 100%, 
.s.u = 0 
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Condition Medication(s) M (in percentages) SD Overall M & SD 
Baseline Combined 108.% 
Loxitane 100.% 
Artane 117.6% 
23.% For Reversals M =139%, 
SD= 12.30% 
0.% Loxitane M =98.9%, 
SJ2 =1.5% 
23.% ArtaneM= 184%, 
SD = 25% 
I 









Treatment B Combined 
Loxitane 
Artane 




































Loxitane M =96%, 
SQ=23% 
Artane M = 148%, 
SQ=l.l% 
- - - - - -
